Research programme: p38 MAP kinase inhibitors - Merck & Co
Alternative Names: ARQ-101Latest Information Update: 20 Jan 2020
At a glance
- Originator ArQule; SignalGene [CEASED]
- Class Oxazoles; Thiazoles
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 23 Sep 2005 Compounds arising from this programme are available for out-licensing (http://www.arqule.com)
- 23 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th ACS-2005) have been added to the Rheumatic Disease pharmacodynamics section